lifestyle.cleanweb.co

Author: Amneal Pharmaceuticals LLC

Amneal Reports First Quarter 2026 Financial Results

May 7, 2026
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance

May 4, 2026
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.

May 3, 2026
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%

May 2, 2026
Amneal to Report First Quarter 2026 Results on May 1, 2026

May 2, 2026
Amneal Announces $2 Million Donation to Support Patient Access to Essential Medicines During Parkinson’s Awareness Month

May 2, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®

April 22, 2026
Amneal to Participate in Upcoming Investor Conference

March 5, 2026
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

February 27, 2026
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index

January 28, 2026